RU2006116511A - Способы и средства для лечения иммуновоспалительных заболеваний - Google Patents
Способы и средства для лечения иммуновоспалительных заболеваний Download PDFInfo
- Publication number
- RU2006116511A RU2006116511A RU2006116511/15A RU2006116511A RU2006116511A RU 2006116511 A RU2006116511 A RU 2006116511A RU 2006116511/15 A RU2006116511/15 A RU 2006116511/15A RU 2006116511 A RU2006116511 A RU 2006116511A RU 2006116511 A RU2006116511 A RU 2006116511A
- Authority
- RU
- Russia
- Prior art keywords
- specified
- composition according
- drug
- composition
- pyrimidopyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (27)
1. Композиция, содержащая тетразамещенный пиримидопиримидин и второе лекарственное средство, выбранное из группы, состоящей из трициклического и тетрациклического антидепрессантов; селективных ингибиторов обратного захвата серотонина (SSRI); ролипрама; ибудиласта; нестероидных противовоспалительных препаратов (NSAID); ингибиторов СОХ-2; биологических веществ; иммуномодуляторов с небольшой молекулой; модифицирующих заболевание антиревматических препаратов (DMARD); ксантинов; антихолинергических соединений; агонистов бета-рецепторов; бронходилятаторов; нестероидных иммунофилин-зависимых иммуносупрессоров; аналогов витамина Д; псораленов; ретиноидов и 5-аминосалициловых кислот, при условии, что когда указанный тетразамещенный пиримидопиримидин является дипиридамолом, указанное второе лекарственное средство не является метотрексатом или аспирином.
2. Композиция по п.1, где указанным тетразамещенным пиримидопиримидином является дипиридамол, мопидамол; дипиридамола моноацетат; 2,6-ди-(2,2-диметил-1,3-диоксолан-4-ил)метокси-4,8-дипиперидинопиримидопиримидин; 2,6-бис-(2,3-диметоксипропокси)-4,8-дипиперидинопиримидопиримидин; 2,6-бис[N,N-ди(2-метокси)этил]-4,6-дипиперидинопиримидопиримидин или 2,6-бис(диэтаноламино)-4,8-ди-4-метоксибензиламинопиримидопиримидин.
3. Композиция по п.1, где указанным трициклическим антидепрессантом является нортриптилин, амоксапин или дезипрамин.
4. Композиция по п.1, где указанным SSRI является пароксетин или флуоксетин.
5. Композиция по п.1, где указанным NSAID является напроксен-натрий, диклофенак-натрий, диклофенак-калий, аспирин, сулиндак, дифлунизал, пироксикам, индометацин, ибупрофен, набуметон, холин магний трисалицилат, натрий салицилат, салицилсалициловую кислоту, фенопрофен, флурбипрофен, кетопрофен, меклофенамат-натрий, мелоксикам, оксапрозин, сулиндак или толметин.
6. Композиция по п.1, где указанным ингибитором СОХ-2 является рофекоксиб, целекоксиб, валдекоксиб или лумиракоксиб.
7. Композиция по п.1, где указанным биологическим веществом является аделимумаб, этанерсепт или инфликсимаб.
8. Композиция по п.1, где указанным DMARD является метотрексат или лефлуномид.
9. Композиция по п.1, где указанным ксантином является теофиллин.
10. Композиция по п.1, где указанным антихолинергическим препаратом является ипратропий или тиотропий.
11. Композиция по п.1, где указанным агонистом бета-рецепторов является ибутерола сульфат, битолтерола мезилат, эпинефрин, формотерола фумарат, изопротеронол, левалбутерола гидрохлорид, метапротеренола сульфат, пирбутерола ацетат, салметерола ксинафоат или тербуталин.
12. Композиция по п.1, где указанным аналогом витамина Д является кальципотриен или кальципотриол.
13. Композиция по п.1, где указанным псораленом является метоксален.
14. Композиция по п.1, где указанным ретиноидом является ацитретин или тазоретен.
15. Композиция по п.1, где указанной 5-аминосалициловой кислотой является мезаламин, сульфасалазин, балсалазида динатриевая соль или олсалазина натриевая соль.
16. Композиция по п.1, где указанным иммуномодулятором с небольшой молекулой является VX 702, SCIO 469, дорамапимод, RO 30201195, SCIO 323, DPC 333, праналказан, микофенолат или меримеподиб.
17. Композиция по п.1, где указанную композицию изготавливают для местного применения.
18. Композиция по п.1, где указанную композицию изготавливают для системного введения.
19. Композиция по п.1, где указанный тетразамещенный пиримидопиримидин или указанное второе лекарственное средство находятся в указанной композиции в низкой дозе.
20. Композиция по п.1, где указанный тетразамещенный пиримидопиримидин или указанное второе лекарственное средство находятся в указанной композиции в высокой дозе.
21. Композиция по п.1, где указанная композиция дополнительно содержит NSAID, ингибитор СОХ-2, биологическое вещество, иммуномодулятор с небольшой молекулой, DMARD, ксантин, антихолинергический препарат, агонист бета-рецепторов, бронходилятатор, нестероидный иммунофилин-зависимый иммуносупрессор, аналог витамина Д, псорален, ретиноид или 5-аминосалициловую кислоту.
22. Способ лечения пациента с диагнозом или с риском развития иммуновоспалительного заболевания, включающий введение пациенту тетразамещенного пиримидопиримидина и второго лекарственного средства, выбранного из группы, состоящей из трициклического и тетрациклического антидепрессантов; селективных ингибиторов обратного захвата серотонина; ролипрама; ибудиласта; NSAID; ингибиторов СОХ-2; биологических веществ; иммуномодуляторов с небольшой молекулой; DMARD; ксантинов; антихолинергических соединений; агонистов бета-рецепторов; бронходилятаторов; нестероидных иммунофилин-зависимых иммуносупрессоров; аналогов витамина Д; псораленов; ретиноидов и 5-аминосалициловых кислот, при условии, что когда указанным тетразамещенным пиримидопиримидином является дипиридамол, то тогда указанным вторым лекарственным средством не является метотрексат или аспирин, где указанный тетразамещенный пиримидопиримидин и указанное второе лекарственное средство вводят одновременно или в течение 14 дней друг от друга в количествах, достаточных для лечения указанного пациента.
23. Способ по п.22, где указанным иммуновоспалительным заболеванием является ревматоидный артрит, болезнь Крона, язвенный колит, астма, хроническое обструктивное заболевание легких, ревматическая полимиалагия, гигантоклеточный артериит, системная красная волчанка, атопический дерматит, рассеянный склероз, тяжелая псевдопаралитическая миастения, псориаз, анкилозирующий спондилит, цирроз или артрит при псориазе.
24. Способ по п.22, где указанный тетразамещенный
пиримидопиримидин и указанное второе лекарственное средство вводят одновременно.
25. Способ по п.22, где указанным тетразамещенным пиримидопиримидином является дипиридамол; мопидамол; дипиридамола моноацетат; 2,6-ди-(2,2-диметил-1,3-диоксолан-4-ил)метокси-4,8-дипиперидинопиримидопиримидин; 2,6-бис-(2,3-диметоксипропокси)-4,8-дипиперидинопиримидопиримидин; 2,6-бис[N,N-ди(2-метокси)этил]-4,6-дипиперидинопиримидопиримидин или 2,6-бис(диэтаноламино)-4,8-ди-4-метоксибензиламинопиримидопиримидин.
26. Способ по п.22, где указанным трициклическим антидепрессантом является нортриптилин, амоксапин или дезипрамин.
27. Способ по п.22, где указанным SSRI является пароксетин или флуоксетин.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51241503P | 2003-10-15 | 2003-10-15 | |
US60/512,415 | 2003-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006116511A true RU2006116511A (ru) | 2007-11-27 |
Family
ID=34465346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006116511/15A RU2006116511A (ru) | 2003-10-15 | 2004-10-13 | Способы и средства для лечения иммуновоспалительных заболеваний |
Country Status (17)
Country | Link |
---|---|
US (3) | US20050119160A1 (ru) |
EP (3) | EP1680121A4 (ru) |
JP (1) | JP2007508391A (ru) |
KR (1) | KR20070001060A (ru) |
CN (1) | CN1889956A (ru) |
AR (1) | AR046291A1 (ru) |
AU (1) | AU2004281729A1 (ru) |
BR (1) | BRPI0415397A (ru) |
CA (1) | CA2542074A1 (ru) |
IL (1) | IL174918A0 (ru) |
IS (1) | IS8451A (ru) |
NO (1) | NO20062003L (ru) |
RU (1) | RU2006116511A (ru) |
SG (1) | SG147442A1 (ru) |
TW (1) | TW200517114A (ru) |
WO (1) | WO2005037203A2 (ru) |
ZA (1) | ZA200603116B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2572709C1 (ru) * | 2015-03-03 | 2016-01-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1448205T3 (da) | 2001-10-05 | 2011-12-12 | Zalicus Inc | Kombinationer til behandling af immunoinflammatoriske sygdomme |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CN1905870A (zh) * | 2003-11-21 | 2007-01-31 | 康宾纳特克斯公司 | 用于治疗炎性病症的方法和试剂 |
US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
US7534806B2 (en) | 2004-12-06 | 2009-05-19 | Avigen, Inc. | Method for treating neuropathic pain and associated syndromes |
WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
CA2640484A1 (en) * | 2006-01-26 | 2007-08-09 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
US20080003213A1 (en) * | 2006-05-22 | 2008-01-03 | Jan Lessem | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels |
TW200814968A (en) * | 2006-06-07 | 2008-04-01 | Combinatorx Inc | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels |
DK2131841T3 (da) * | 2007-01-30 | 2012-10-15 | Avigen Inc | Fremgangsmåder til behandling af akut smerte |
WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
WO2008138123A1 (en) * | 2007-05-09 | 2008-11-20 | Thomas David Y | Screening assay to identify correctors of protein trafficking defects |
US20090005358A1 (en) * | 2007-06-26 | 2009-01-01 | Jan Lessem | Compositions and methods for treating medical conditions |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
CA2694987A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
US20090053168A1 (en) * | 2007-07-17 | 2009-02-26 | Richard Rickles | Treatments of b-cell proliferative disorders |
CA2737131A1 (en) * | 2007-09-19 | 2009-03-26 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
MX2010006724A (es) * | 2007-12-17 | 2010-09-07 | Combinatorx Inc | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. |
WO2009094641A2 (en) * | 2008-01-24 | 2009-07-30 | Dor Biopharma, Inc. | Topically active steroids for use in interstitial pulmonary fibrosis |
US9314469B2 (en) * | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
AU2010259184B2 (en) * | 2009-06-09 | 2015-08-13 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9867800B2 (en) | 2012-08-10 | 2018-01-16 | Hallstar Innovations Corp. | Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen |
US9145383B2 (en) | 2012-08-10 | 2015-09-29 | Hallstar Innovations Corp. | Compositions, apparatus, systems, and methods for resolving electronic excited states |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150031712A1 (en) | 2013-03-12 | 2015-01-29 | Moshe Rogosnitzky | Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same |
GB201309379D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
US10322129B2 (en) | 2015-06-08 | 2019-06-18 | O.D. Ocular Discovery Ltd. | Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
BR112019013244A2 (pt) | 2016-12-28 | 2019-12-24 | Tonix Pharma Holdings Ltd | sais e polimorfos de oxalato de tianeptina |
US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
US20190247369A1 (en) * | 2018-02-12 | 2019-08-15 | Medicinova, Inc. | Methods of suppressing myeloid-derived suppressor cells in patients |
CN109568564B (zh) * | 2018-12-29 | 2022-04-29 | 武汉天天好生物制品有限公司 | 一种多肽组件复合物、多肽组件双层片及制备工艺和应用 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
EP4236949A1 (en) * | 2020-10-30 | 2023-09-06 | The Board of Trustees of the Leland Stanford Junior University | Drugs targeting inflammation for the treatment of osteoarthritis and other inflammatory diseases |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US532248A (en) | 1895-01-08 | powell | ||
US2129401A (en) | 1937-09-09 | 1938-09-06 | Botinger Fred | Flexible utility ladder |
US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
JPS5229318B2 (ru) | 1972-03-30 | 1977-08-01 | ||
AU496759B2 (en) | 1972-12-27 | 1978-10-26 | Schering Aktiengesellschaft | New pregnan-21-oic derivatives |
US4107306A (en) | 1973-01-16 | 1978-08-15 | The Regents Of The University Of Michigan | Process for treating proliferative skin disease |
US4034087A (en) | 1973-12-17 | 1977-07-05 | The Regents Of The University Of Michigan | Pharmaceutical composition and process of treatment |
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4193926A (en) | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
US4097483A (en) | 1974-11-01 | 1978-06-27 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolo 1,5-a!pyridines |
US3956296A (en) | 1974-12-11 | 1976-05-11 | A. H. Robins Company, Incorporated | 1-Substituted-4-benzylpiperidines |
US3934036A (en) | 1975-01-23 | 1976-01-20 | Kyorin Seiyaku Kabushiki Kaisha | N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent |
JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
SE445174B (sv) | 1978-03-07 | 1986-06-09 | Sandoz Ag | Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans |
NL171194C (nl) | 1978-05-23 | 1983-02-16 | Giesen Metaalgieterij | Warmwater-ketel, bijvoorbeeld een centrale verwarmingsketel. |
EP0005911B1 (en) * | 1978-05-26 | 1982-02-17 | Imperial Chemical Industries Plc | Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture |
PH16099A (en) | 1979-03-06 | 1983-06-24 | Yamanouchi Pharma Co Ltd | Guanidinothiazole compounds,process for preparing them and medical composition containing them |
JPS6056143B2 (ja) | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
US4285958A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4285957A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
US4254130A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
US4394508A (en) | 1980-06-07 | 1983-07-19 | Bristol-Myers Company | Chemical compounds |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4384996A (en) | 1981-01-09 | 1983-05-24 | Sandoz Ltd. | Novel cyclosporins |
US4510309A (en) | 1981-03-03 | 1985-04-09 | Bristol-Myers Company | Histamine H2 -antagonists |
BG36086A1 (en) | 1982-01-19 | 1984-09-14 | Glbov | Method for inducing interferon |
JPS59167590A (ja) | 1983-03-14 | 1984-09-21 | Kyorin Pharmaceut Co Ltd | ピラゾロ〔1,5−a〕ピリジン誘導体、その製法及びそれを含有する治療剤 |
US4440933A (en) | 1983-03-16 | 1984-04-03 | Bristol-Myers Company | Process for preparing 1,2,5-thiadiazoles |
GB8321157D0 (en) | 1983-08-05 | 1983-09-07 | Fordonal Sa | Piperidine derivatives |
US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
JPS60174716A (ja) | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
US4554271A (en) | 1984-02-24 | 1985-11-19 | The Upjohn Company | Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome |
US4933438A (en) | 1984-02-29 | 1990-06-12 | University Of Florida | Brain-specific analogues of centrally acting amines |
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
US5254562A (en) | 1984-12-03 | 1993-10-19 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
GB8509276D0 (en) | 1985-04-11 | 1985-05-15 | Smith Kline French Lab | Pyridine derivatives |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US4742175A (en) | 1986-05-07 | 1988-05-03 | Merrell Dow Pharmaceuticals Inc. | Preparation of polymorphically pure terfenadine |
DE3627423A1 (de) | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
US5120716A (en) | 1987-02-23 | 1992-06-09 | Shiseido Company Ltd. | Percutaneous absorption promoting agent and dermatologic preparation containing the same |
DE3706399A1 (de) | 1987-02-27 | 1988-09-08 | Boehringer Ingelheim Kg | Mittel mit antidepressiver wirkung |
US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US4798823A (en) | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
JP2577049B2 (ja) | 1987-06-04 | 1997-01-29 | 三共株式会社 | シクロスポリン製剤 |
US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
US5227467A (en) | 1987-08-03 | 1993-07-13 | Merck & Co., Inc. | Immunosuppressive fluorinated cyclosporin analogs |
US4833138A (en) | 1987-10-23 | 1989-05-23 | Washington University | Phenothiazinealkaneamines for treatment of neurotoxic injury |
AU3554089A (en) | 1988-04-27 | 1989-11-24 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
US5242921A (en) | 1988-04-27 | 1993-09-07 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
GB8813032D0 (en) * | 1988-06-02 | 1988-07-06 | Boehringer Ingelheim Int | Antiviral pharmaceutical composition |
GB8819626D0 (en) * | 1988-08-18 | 1988-09-21 | Boehringer Ingelheim Int | Pharmaceutical composition for treatment of tumours |
KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
US5342625A (en) | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US6007840A (en) | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US4908372A (en) | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
US4963541A (en) | 1989-02-22 | 1990-10-16 | Abbott Laboratories | Pyrimido-pyrimidine lipoxygenase inhibiting compounds |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5284826A (en) | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208228A (en) | 1989-11-13 | 1993-05-04 | Merck & Co., Inc. | Aminomacrolides and derivatives having immunosuppressive activity |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5122511A (en) | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
PT98990A (pt) | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5143918A (en) | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
US5626863A (en) | 1992-02-28 | 1997-05-06 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
DE4034218A1 (de) | 1990-10-27 | 1992-04-30 | Merck Patent Gmbh | Verfahren zur herstellung von carebastin |
WO1992016226A1 (en) | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5565560A (en) | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
US5262533A (en) | 1991-05-13 | 1993-11-16 | Merck & Co., Inc. | Amino O-aryl macrolides having immunosuppressive activity |
US5250678A (en) | 1991-05-13 | 1993-10-05 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
US5162334A (en) | 1991-05-13 | 1992-11-10 | Merck & Co., Inc. | Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity |
US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
US5120725A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
US5169851A (en) | 1991-08-07 | 1992-12-08 | American Home Products Corporation | Rapamycin analog as immunosuppressants and antifungals |
US5189042A (en) | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
US5208241A (en) | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5270047A (en) * | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5284840A (en) | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkylidene macrolides having immunosuppressive activity |
RO116043B1 (ro) | 1992-08-03 | 2000-10-30 | Sepracor Inc | Compozitie farmaceutica |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
ES2261871T3 (es) | 1993-06-24 | 2006-11-16 | Amr Technology, Inc. | Procedimiento para preparar compuestos utiles como intermediarios. |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
US6022852A (en) | 1993-10-22 | 2000-02-08 | Hexal Ag | Pharmaceutical composition containing cyclosporin A |
TW249754B (ru) | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
DE4430128A1 (de) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
US5693648A (en) | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
US5696130A (en) | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
FR2732223B1 (fr) | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
AU5772196A (en) | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
DE19537012A1 (de) | 1995-10-04 | 1997-04-10 | Dietl Hans | Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung |
US6153754A (en) | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US6201124B1 (en) | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US5709797A (en) | 1996-06-05 | 1998-01-20 | Poli Industria Chimica S.P.A. | Method of isolating cyclosporins |
US6235706B1 (en) | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5874437A (en) | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
AU722480B2 (en) | 1996-11-01 | 2000-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US5792476A (en) | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
US6054487A (en) | 1997-03-18 | 2000-04-25 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
JP2002502421A (ja) | 1997-06-05 | 2002-01-22 | イーライ・リリー・アンド・カンパニー | 血栓障害の処置方法 |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
EP2042161A1 (en) | 1997-10-01 | 2009-04-01 | Novadel Pharma Inc. | Propellant-free spray composition comprising anti-emetic agent |
US20030077229A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
ATE423130T1 (de) | 1997-10-08 | 2009-03-15 | Isotechnika Inc | Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien |
ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
US6380207B2 (en) | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
WO1999042104A1 (en) | 1998-02-23 | 1999-08-26 | Fujisawa Pharmaceutical Co., Ltd. | Use of macrolide compounds for treating glaucoma |
CA2322824A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
WO1999062537A1 (en) | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
CN1246335A (zh) | 1998-08-28 | 2000-03-08 | 冀聪韬 | 一种用于治疗皮肤病药物的制作方法 |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
US6677326B2 (en) | 1999-03-15 | 2004-01-13 | Arakis, Ltd. | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
GEP20053474B (en) | 1999-04-30 | 2005-03-25 | Pfizer Prod Inc | Glucocorticoid Receptor Modulators |
ES2206254T3 (es) | 1999-07-01 | 2004-05-16 | Italfarmaco S.P.A. | Complejos de paroxetina con ciclodextrinas o derivados de ciclodextrinas. |
AU6078500A (en) * | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
US6593480B2 (en) | 1999-09-01 | 2003-07-15 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
EP1216037A2 (en) | 1999-09-21 | 2002-06-26 | Emory University | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
EP1093814A1 (en) | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
CA2392085A1 (en) | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
ITMI992711A1 (it) * | 1999-12-27 | 2001-06-27 | Novartis Ag | Composti organici |
WO2001047572A2 (en) | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
WO2001054679A2 (en) | 2000-01-27 | 2001-08-02 | Children's Hospital Research Foundation | Transdermal composition containing an anesthetic and a vasodilator agent |
DE10012555A1 (de) | 2000-03-15 | 2001-09-20 | Merck Patent Gmbh | Glucocorticoide in einer Modified Release-Formulierung |
US6290445B1 (en) | 2000-04-18 | 2001-09-18 | Avibank Mfg., Inc. | Non-removable structural threaded fastener with threads of lesser outer diameter than the shank and method of forming same |
WO2002022127A1 (en) | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
IL180679A0 (en) | 2000-10-27 | 2009-02-11 | Pfizer Prod Inc | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
JP2002193911A (ja) | 2000-10-28 | 2002-07-10 | Pfizer Prod Inc | グルココルチコイドレセプターモジュレーター |
TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
EP1370211A4 (en) | 2001-03-02 | 2005-02-09 | Bristol Myers Squibb Co | SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP |
US6759058B1 (en) | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
US6960357B2 (en) | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
CA2453399A1 (en) * | 2001-07-09 | 2003-01-23 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory disorders |
GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
DK1448205T3 (da) | 2001-10-05 | 2011-12-12 | Zalicus Inc | Kombinationer til behandling af immunoinflammatoriske sygdomme |
US20030129250A1 (en) | 2001-11-20 | 2003-07-10 | Advanced Inhalation Research Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US20030157061A1 (en) * | 2001-12-05 | 2003-08-21 | Pharmacia Corporation | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor |
EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
CA2474016A1 (en) * | 2002-02-04 | 2003-08-14 | Pharmacia Corporation | A combination for treating cold and cough |
WO2004004734A1 (en) | 2002-07-10 | 2004-01-15 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
US20040180812A1 (en) | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
CA2511963A1 (en) | 2002-12-31 | 2004-07-22 | Larry L. Augsburger | Methods for making pharmaceutical dosage forms containing active cushioning components |
WO2004069254A2 (en) | 2003-02-07 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
US20050058688A1 (en) | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
CA2538023A1 (en) * | 2003-09-24 | 2005-04-07 | Combinatorx, Incorporated | Therapeutic regimens for administering drug combinations |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CA2640484A1 (en) | 2006-01-26 | 2007-08-09 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith |
ES2533563T5 (es) | 2006-01-27 | 2018-07-24 | Adare Pharmaceuticals, Inc. | Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos |
JP2009529053A (ja) | 2006-03-07 | 2009-08-13 | コンビナトアールエックス インコーポレーティッド | 免疫炎症性障害の処置のための組成物および方法 |
CA2737131A1 (en) | 2007-09-19 | 2009-03-26 | Zalicus Inc. | Therapeutic regimens for the treatment of immunoinflammatory disorders |
-
2004
- 2004-10-12 TW TW093130850A patent/TW200517114A/zh unknown
- 2004-10-13 ZA ZA200603116A patent/ZA200603116B/en unknown
- 2004-10-13 EP EP04809944A patent/EP1680121A4/en not_active Withdrawn
- 2004-10-13 CN CNA2004800366065A patent/CN1889956A/zh active Pending
- 2004-10-13 CA CA002542074A patent/CA2542074A1/en not_active Abandoned
- 2004-10-13 AU AU2004281729A patent/AU2004281729A1/en not_active Abandoned
- 2004-10-13 KR KR1020067009276A patent/KR20070001060A/ko not_active Application Discontinuation
- 2004-10-13 JP JP2006535594A patent/JP2007508391A/ja active Pending
- 2004-10-13 RU RU2006116511/15A patent/RU2006116511A/ru not_active Application Discontinuation
- 2004-10-13 WO PCT/US2004/033656 patent/WO2005037203A2/en active Application Filing
- 2004-10-13 EP EP10013062A patent/EP2301628A1/en not_active Withdrawn
- 2004-10-13 BR BRPI0415397-9A patent/BRPI0415397A/pt not_active IP Right Cessation
- 2004-10-13 EP EP09002049A patent/EP2070550A1/en not_active Withdrawn
- 2004-10-13 SG SG200807704-2A patent/SG147442A1/en unknown
- 2004-10-15 US US10/966,228 patent/US20050119160A1/en not_active Abandoned
- 2004-10-20 AR ARP040103746A patent/AR046291A1/es unknown
-
2006
- 2006-04-10 IL IL174918A patent/IL174918A0/en unknown
- 2006-05-04 NO NO20062003A patent/NO20062003L/no not_active Application Discontinuation
- 2006-05-11 IS IS8451A patent/IS8451A/is unknown
- 2006-09-07 US US11/517,593 patent/US8080553B2/en not_active Expired - Fee Related
-
2011
- 2011-11-09 US US13/292,669 patent/US20120058979A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2572709C1 (ru) * | 2015-03-03 | 2016-01-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом |
Also Published As
Publication number | Publication date |
---|---|
AU2004281729A1 (en) | 2005-04-28 |
WO2005037203A2 (en) | 2005-04-28 |
US20070010502A1 (en) | 2007-01-11 |
CN1889956A (zh) | 2007-01-03 |
ZA200603116B (en) | 2008-06-25 |
IS8451A (is) | 2006-05-11 |
WO2005037203A3 (en) | 2006-03-16 |
CA2542074A1 (en) | 2005-04-28 |
NO20062003L (no) | 2006-07-07 |
BRPI0415397A (pt) | 2006-12-19 |
SG147442A1 (en) | 2008-11-28 |
EP1680121A4 (en) | 2007-12-26 |
US20050119160A1 (en) | 2005-06-02 |
JP2007508391A (ja) | 2007-04-05 |
EP1680121A2 (en) | 2006-07-19 |
EP2301628A1 (en) | 2011-03-30 |
TW200517114A (en) | 2005-06-01 |
IL174918A0 (en) | 2008-04-13 |
US20120058979A1 (en) | 2012-03-08 |
US8080553B2 (en) | 2011-12-20 |
AR046291A1 (es) | 2005-11-30 |
EP2070550A1 (en) | 2009-06-17 |
KR20070001060A (ko) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006116511A (ru) | Способы и средства для лечения иммуновоспалительных заболеваний | |
Bortolotto et al. | Long-term exposure to paraquat alters behavioral parameters and dopamine levels in adult zebrafish (Danio rerio) | |
Seino et al. | β‐Cell signalling and insulin secretagogues: A path for improved diabetes therapy | |
LeRoith et al. | Diabetes mellitus: a fundamental and clinical text | |
Peek et al. | Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice | |
Dakroub et al. | Visfatin: A possible role in cardiovasculo-metabolic disorders | |
Sprague et al. | Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release | |
Sweet et al. | Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient | |
Wang et al. | Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway | |
Vernochet et al. | Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines | |
Pala et al. | The roles of primary cilia in cardiovascular diseases | |
Gu et al. | Fructose downregulates miR‐330 to induce renal inflammatory response and insulin signaling impairment: attenuation by morin | |
Miville-Godbout et al. | Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice | |
Otani et al. | Recent approaches to gout drug discovery: an update | |
Note et al. | Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single-and three dual-NRTI treatments | |
Beikoghli Kalkhoran et al. | Oestrogenic regulation of mitochondrial dynamics | |
Pomytkin et al. | Brain insulin resistance: focus on insulin receptor-mitochondria interactions | |
Ren et al. | Two standardized fractions of Gardenia jasminoides Ellis with rapid antidepressant effects are differentially associated with BDNF up-regulation in the hippocampus | |
Kwon et al. | Roles of histone acetylation modifiers and other epigenetic regulators in vascular calcification | |
Salmina et al. | Early life stress and metabolic plasticity of brain cells: impact on neurogenesis and angiogenesis | |
Yamashiro et al. | pH-dependent pyridoxine transport by SLC19A2 and SLC19A3: Implications for absorption in acidic microclimates | |
Alshammari | The ketamine antidepressant story: new insights | |
Otani et al. | Recent advances in the treatment of pulmonary arterial hypertension | |
Alsaif et al. | Synthesis of Novel Diclofenac Hydrazones: Molecular Docking, Anti‐Inflammatory, Analgesic, and Ulcerogenic Activity | |
Brahadeeswaran et al. | NLRP3: a new therapeutic target in alcoholic liver disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090302 |
|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090302 |